DGAP-News: United States Army and Cytos Biotechnology Collaborate on Malaria Vaccines Research
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Alliance
United States Army and Cytos Biotechnology Collaborate on Malaria
Vaccines Research
31.03.2011 / 07:00
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, March 31, 2011 - Cytos Biotechnology Ltd
(SIX:CYTN) announced today that it has entered a Cooperative Research and
Development Agreement (CRADA) for the preclinical development of a malaria
vaccine with the Walter Reed Army Institute of Research (WRAIR). Cytos
Biotechnology will provide its virus-like particle (VLP) based vaccination
technology and expertise whilst WRAIR will contribute a malaria antigen
candidate. Vaccine candidates generated by Cytos Biotechnology will be
tested in preclinical models of malaria disease by WRAIR.
Dr Martin Bachmann, CSO of Cytos Biotechnology commented 'The WRAIR is the
largest and most diverse biomedical research laboratory in the US
Department of Defense and we keenly welcome the opportunity to work with
them in malaria vaccine R&D. Malaria is a major disease burden for people
living in at-risk areas and it poses a significant threat to military
personnel serving in such regions and to travelers. Consequently, the
development of new vaccines to prevent malaria is an important area of
focus for vaccine R&D. This collaboration is our second malaria vaccine
partnership with leading research institutes in the United States of
America following the recent announcement of our collaboration with the NIH
and SAIC. This new collaboration demonstrates the continuing attractiveness
of the VLP-platform for partnering in the eyes of leading biomedical
organizations in academia, government agencies, and industry.'
For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
About Malaria
More than 40 percent of the world's population lives in areas where there
is a risk of contracting malaria. Nearly one million people die of malaria
every year, mostly infants, young children and pregnant women and most of
them in Africa. Approximately 300-500 million cases of clinical malaria
occur each year. Malaria accounts for at least $12 billion in economic
losses each year in Africa, and a reduction in annual economic growth
estimated at 1.3 percent. (Source: NIH Website)
About WRAIR
The Walter Reed Army Institute of Research (WRAIR) is the largest and most
diverse biomedical research laboratory in the United Sates of America
Department of Defense.
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which five are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 76 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'will be tested', 'candidates',
'intended', 'designed' or other similar expressions. These forward-looking
statements are subject to a variety of significant uncertainties, including
scientific, business, economic and financial factors, and therefore actual
results may differ significantly from those presented. There can be no
assurance that any therapeutic entities will enter clinical trials, that
clinical trial results will be predictive for future results, that
therapeutic entities will be the subject of filings for regulatory
approval, that any drug candidates will receive marketing approval from the
U.S. Food and Drug Administration or equivalent regulatory authorities, or
that drugs will be marketed successfully. Against the background of these
uncertainties readers should not rely on forward-looking statements. The
company assumes no responsibility to update forward-looking statements or
adapt them to future events or developments. This document does not
constitute an offer or invitation to subscribe or purchase any securities
of Cytos Biotechnology Ltd.
End of Corporate News
---------------------------------------------------------------------
31.03.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Regulierter Markt in SIX; Freiverkehr in
Berlin, München, Stuttgart; Open Market in
Frankfurt
End of News EquityStory AG News-Service
---------------------------------------------------------------------
117679 31.03.2011
Datum: 31.03.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 33654
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: United States Army and Cytos Biotechnology Collaborate on Malaria Vaccines Research"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
